Quick Answer
Coherus Oncology, Inc. reported Research And Development Expense of $108.89 million for the year ending 2025.
- Coherus Oncology, Inc. showed an increase of +18.6% in Research And Development Expense from 2024 to 2025.
- This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Coherus Oncology, Inc.'s Research And Development Expense has grown by 212.1%.
- Historical annual values: Fiscal year 2025: $108.89 million | Fiscal year 2024: $91.83 million | Fiscal year 2023: $109.44 million | Fiscal year 2022: $199.36 million | Fiscal year 2021: $363.11 million | Fiscal year 2020: $142.76 million | Fiscal year 2019: $94.19 million | Fiscal year 2018: $110.24 million | Fiscal year 2017: $162.39 million | Fiscal year 2016: $254.44 million | Fiscal year 2015: $213.06 million | Fiscal year 2014: $78.22 million | Fiscal year 2013: $31.28 million | Fiscal year 2012: $34.89 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: